v3.25.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss $ (12,298,411) $ (4,234,742)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 2,454,686 1,893,602
Interest from amortization of loan issuance costs 90,124 120,833
Amortization of fair value of loan 90,321 0
Loss on extinguishment of debt 506,280 0
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) 8,841,529 0
Loss on disposal of property and equipment 4,016 78,437
Stock-based compensation on stock options, RSUs & RSAs, net 698,610 506,020
Provision for credit losses (11,573) 0
Change in operating lease assets and liabilities (129,028) (57,653)
Inventory write-offs to allowance 147,896 135,625
Deferred taxes (66,155) (2,795)
Changes in operating assets and liabilities, net of acquisitions:    
Trade accounts receivable 883,396 (350,703)
Other current assets 16,958 41,286
Inventories (780,477) (13,005)
Prepaid expenses and deposits (24,253) (123,598)
Accounts payable and accrued liabilities 1,257,002 (430,923)
Net cash provided by (used in) operating activities 1,680,921 (2,437,616)
Cash flows from investing activities:    
Purchase of property and equipment (944,909) (160,155)
Proceeds from sale of equipment 0 10,648
Net cash used in investing activities (944,909) (149,507)
Cash flows from financing activities:    
Proceeds from sale of common stock from Employee Stock Purchase Plan 0 10,372
Proceeds from issuance of common stock under public equity placement, net of fees 65,340,834 0
Proceeds from issuance of common stock under private equity placement, net of fees 7,894,045 0
Deferred payment for acquisition of Visimid 0 (125,000)
Borrowings on loans payable 0 3,000,000
Loan issuance costs 0 (300,000)
Payments on loans payable (5,413,819) (106,486)
Repayment of finance lease obligations (107,712) (89,705)
Net cash provided by financing activities 67,713,348 2,389,181
Effect of exchange rate on cash and cash equivalents 246,075 (81,260)
Change in cash and cash equivalents 68,695,435 (279,202)
Cash and cash equivalents, beginning of period 4,877,036 3,480,268
Cash and cash equivalents, end of period 73,572,471 3,201,066
Supplemental disclosure of cash flow information:    
Interest paid in cash 373,398 40,838
Income taxes paid 170,272 61,427
Supplemental disclosure of non-cash investing & financing activities:    
Purchase of equipment through finance lease arrangements 41,901 93,048
Operating right-of-use assets acquired in exchange for operating lease liabilities 435,733 0
Issuance of common stock for acquisition of Visimid $ 350,000 $ 321,358